Trials / Not Yet Recruiting
Not Yet RecruitingNCT06807749
Adjuvant Treatment in Premenopausal Breast Cancer
PrEmenopausal bReaSt cancEr adjuVant thERapy Benefit According to OncotypE DX Test
- Status
- Not Yet Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 800 (estimated)
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS · Academic / Other
- Sex
- Female
- Age
- 60 Years
- Healthy volunteers
- Not accepted
Summary
Multicentric retroprospective observational study to collect outcome in premenopausal breast cancer patients who undergone the 21-multigene assay Oncotype DX from 1st January 2013 to 31st December 2022 and adjuvant treatment.
Detailed description
Premenopausal patients who undergone the 21-multigene assay Oncotype DX from 1st January 2013 to 31st December 2022 with any Recurrence Score (RS) and pathological nodal status pN0/pN1 will be included in the study. The study will collect clinical-pathological, genomic characteristics, adjuvant treatments (chemotherapy, endocrine therapy with/without OFS), and survival outcome (iDFS).
Conditions
Timeline
- Start date
- 2025-04-01
- Primary completion
- 2026-09-01
- Completion
- 2027-09-01
- First posted
- 2025-02-04
- Last updated
- 2025-03-24
Locations
1 site across 1 country: Italy
Source: ClinicalTrials.gov record NCT06807749. Inclusion in this directory is not an endorsement.